about
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Novel immunotherapies for hematologic malignanciesCurrent status of hematopoietic stem cell transplant in chronic myeloid leukemiaStromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in miceGenetic barriers in transplantation medicineImmune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationSurvivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignanciesGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveFludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialIrradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Characterization of a new mouse model for peripheral T cell lymphoma in humans.Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host diseaseGeneration of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantTreatment of High-Risk T-NHL with Stem Cell Transplantation: A Single Center Experience.Impaired CD8(+) T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progressionOptions for T-cell based therapies.Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.Mesenchymal stromal cells: a new tool against graft-versus-host disease?Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedureImmune restoration following hematopoietic stem cell transplantation: an evolving target.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Recent advances in the treatment of graft-versus-host disease.An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissuesDendritic cells in allogeneic hematopoietic stem cell transplantation.Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy.Adoptive T-cell transfer in cancer immunotherapy.New insights into antigen specific immunotherapy for chronic myeloid leukemiaAutologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusionsCellular therapies in acute lymphoblastic leukemiaOptimization of allogeneic transplant conditioning: not the time for dogma.
P2860
Q26826830-DA9250E9-7BE5-469B-8E0E-EEA402544DC5Q26830857-ED92DB94-A968-43C4-BE49-AA4785EFE50FQ27004436-0752C52D-BAAE-4B6A-8C4C-7CB4839C1247Q27010475-88B5D251-FC7C-4EFA-B957-B84F7F78AF25Q27305136-E8365E2D-F5DA-47C9-8CD7-1BABABC94C54Q28069956-811C246E-6387-43A5-9826-0B0AF2B1858CQ28072627-F92D92BB-D139-4A11-B1C0-18730B1B7FCDQ28251858-769675AF-6E67-496B-AF1F-666FA12C2D62Q28388806-58F4E180-62B2-434F-882F-8317B071E476Q30543777-FCE2BEB4-7B43-44F8-8754-54B9C6D2F61AQ33750829-D633244A-5FED-4B4F-BD7B-0C553DFBC6D7Q33770125-6A44C976-4DBE-48BF-A25F-61750E8303A1Q34097906-70B51721-0ACB-40E8-B8C5-4C75EFC4A9FEQ34245299-DDEE9419-BC2F-484C-BD59-820A42EA4083Q34272547-2A76186F-2DBB-4206-8BF2-BAE2DC11E275Q34635978-D3E03489-AAFA-439C-AA99-843308D6FE37Q34766846-92CE4DED-DB34-4B93-8FE8-421005A49A68Q34779037-7EFB858B-65D2-488C-8DBA-389517009275Q35083003-879217D5-914A-4C13-94AC-5E28A962EFE9Q35101948-C41788EB-C237-40EA-8AB6-6D0D9860D37FQ35651730-CE1E0F01-B9BA-4512-83DC-5FDA8B838AB1Q35698863-787D8CA8-266C-407F-82F3-864B01CD433FQ35813115-E035CDAC-DD7A-4C62-B640-46BDD6C24753Q35828638-118FEF59-5782-4A98-BBB8-6DCFE28773BAQ35835657-10F3D6E5-8004-49F8-B1BB-495A36AF9E45Q35848391-1E856401-0A2C-4FDC-8693-C446E4AD1D6DQ35849500-6244E6CD-4B32-44FB-BAEF-A66DF603FD31Q35900929-93071C6F-E949-47C9-A879-46886F97D2F5Q36038463-0493DF72-15EF-43E2-9221-B73CA73F3EADQ36075296-CBE2E635-30E4-4921-AB22-2C5CB5C01712Q36110355-05D612E6-12EB-46F2-970F-1467FA0A0AB9Q36148596-8D247995-339B-4629-9BAB-21FBCBE48289Q36228795-3EB6D397-AEBC-48D5-808E-35F4B282EA54Q36272587-4E2F0723-0441-4FF0-A38D-DC25F55D6F4DQ36366589-157C5236-C658-43DC-ADC7-E548B88AB1EEQ36471818-4082C0EE-E9D8-4D6C-B660-C9BD305228DFQ36513477-8DF05B1A-AE52-4AE4-9D89-F5409EAD9470Q36546883-589AC16E-0CF9-4B23-9D30-5E444C61877AQ36552098-1875C4A2-35DE-4708-83AE-FFB70E676699Q36556498-2502A392-933F-473C-AD75-4C71DC2353D1
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Graft-versus-leukemia reactions in allogeneic chimeras.
@ast
Graft-versus-leukemia reactions in allogeneic chimeras.
@en
type
label
Graft-versus-leukemia reactions in allogeneic chimeras.
@ast
Graft-versus-leukemia reactions in allogeneic chimeras.
@en
prefLabel
Graft-versus-leukemia reactions in allogeneic chimeras.
@ast
Graft-versus-leukemia reactions in allogeneic chimeras.
@en
P2093
P1433
P1476
Graft-versus-leukemia reactions in allogeneic chimeras.
@en
P2093
A John Barrett
Christoph Schmid
Dolores J Schendel
Hans-Jochem Kolb
P304
P356
10.1182/BLOOD-2003-02-0342
P407
P577
2003-09-04T00:00:00Z